Sutro Biopharma (STRO) EBT (2017 - 2026)

Sutro Biopharma has reported EBT for 9 years, with the latest figure at -$46.8 million in Q4 2025.

• Quarterly EBT rose 33.16% year-over-year to -$46.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$182.8 million (up 18.77% YoY) and the FY2025 annual result came in at -$191.2 million, up 15.07% from the prior year.
• EBT climbed to -$46.8 million in Q4 2025 per STRO's latest filing, from -$56.9 million in the prior quarter.
• Over five years, EBT peaked at $46.9 million in Q4 2023 and troughed at -$70.1 million in Q4 2024.
• A 5-year average of -$35.4 million and a median of -$38.7 million in 2022 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2023: EBT slumped 282.18% in 2022, then jumped 235.49% in 2023.
• Over 5 years, EBT stood at -$38.1 million in 2021, then climbed by 9.26% to -$34.6 million in 2022, then surged by 235.49% to $46.9 million in 2023, then slumped by 249.53% to -$70.1 million in 2024, then soared by 33.16% to -$46.8 million in 2025.
• According to Business Quant data, EBT over the past three periods registered -$46.8 million, -$56.9 million, and -$11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.